Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis

BACKGROUND: Bevacizumab (Bev) plays the central role of the adjuvant therapy for patients with ovarian carcinoma. The aim of our study was to examine whether differences in the administration of Bev influence the prognosis of patients. METHODS: Patients with ovarian carcinoma who received treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Suminokura, Jin, Miyamoto, Morikazu, Yoshikawa, Tomoyuki, Kouta, Hiroko, Kikuchi, Yoshihiro, Hada, Taira, Ishibashi, Hiroki, Ito, Tsubasa, Iwahashi, Hideki, Kakimoto, Soichiro, Suzuki, Rie, Matsuura, Hiroko, Kishimoto, Naohisa, Takano, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849038/
https://www.ncbi.nlm.nih.gov/pubmed/35172766
http://dx.doi.org/10.1186/s12885-022-09271-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849038/
https://www.ncbi.nlm.nih.gov/pubmed/35172766
http://dx.doi.org/10.1186/s12885-022-09271-3

Ejemplares similares